API




Key Events

ID Title Short name Biological organization
3 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Cellular
8 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Cellular
9 Activation, 5HT2c Activation, 5HT2c Molecular
10 Accumulation, Acetylcholine in synapses Accumulation, Acetylcholine in synapses Cellular
12 Inhibition, Acetylcholinesterase (AchE) Inhibition, Acetylcholinesterase (AchE) Cellular
17 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways Molecular
18 Activation, AhR Activation, AhR Molecular
21 Altered regulation, Alpha hemoglobin Altered regulation, Alpha hemoglobin Cellular
25 Agonism, Androgen receptor Agonism, Androgen receptor Molecular
26 Antagonism, Androgen receptor Antagonism, Androgen receptor Molecular
27 N/A, Androgen receptor, Antagonism N/A, Androgen receptor, Antagonism Molecular
28 Reduction, Angiogenesis Reduction, Angiogenesis Molecular
29 Reduction in, Angiogenic sprouts Reduction in, Angiogenic sprouts
35 Decrease, Aromatase (Cyp19a1) Decrease, Aromatase (Cyp19a1) Cellular
36 Inhibition, Aromatase Inhibition, Aromatase Molecular
39 Induction, Ataxia, paralysis, or hyperactivity Induction, Ataxia, paralysis, or hyperactivity Organ
40 Decreased, ATP production Decreased, ATP production Cellular
41 Inhibition, Bile Salt Export Pump (ABCB11) Inhibition, Bile Salt Export Pump (ABCB11) Molecular
42 Up Regulation, Biliary excretion Up Regulation, Biliary excretion
46 Accumulation, Biological membranes Accumulation, Biological membranes Cellular
49 Reduction, Ca and HCO3 transport to shell gland Reduction, Ca and HCO3 transport to shell gland Tissue
50 Increase, Ca++ (intracellular) Increase, Ca++ (intracellular) Cellular
51 Inhibition, Ca++ ATPase Inhibition, Ca++ ATPase Molecular
52 Decreased, Calcium influx Decreased, Calcium influx Cellular
54 Up Regulation, CD36 Up Regulation, CD36 Molecular
55 N/A, Cell injury/death N/A, Cell injury/death Cellular
57 Proliferation, Cell proliferation in the absence of cytotoxicity Proliferation, Cell proliferation in the absence of cytotoxicity Cellular
59 Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis
60 Induction, Chitin degradation and resorption Induction, Chitin degradation and resorption
62 Induction, Chitin synthesis Induction, Chitin synthesis
64 Reduction, Ionotropic GABA receptor chloride channel conductance Reduction, Ionotropic GABA receptor chloride channel conductance Cellular
66 Activation, ChREBP Activation, ChREBP Molecular
68 Accumulation, Collagen Accumulation, Collagen Tissue
71 Activation, Constitutive androstane receptor, NR1l3 Activation, Constitutive androstane receptor, NR1l3
75 N/A, Covalent binding to protein, possibly lysine residue N/A, Covalent binding to protein, possibly lysine residue Molecular
77 Production, Critical Metabolites (CGA 330050 and CGA 265307) Production, Critical Metabolites (CGA 330050 and CGA 265307) Cellular
78 Reduction, Cumulative fecundity and spawning Reduction, Cumulative fecundity and spawning Individual
79 Inhibition, Cyclooxygenase activity Inhibition, Cyclooxygenase activity Molecular
80 Up Regulation, CYP1A1 Up Regulation, CYP1A1 Molecular
84 Up Regulation, CYP1B1 Up Regulation, CYP1B1 Molecular
87 Release, Cytokine Release, Cytokine Cellular
89 Synthesis, De Novo FA Synthesis, De Novo FA Cellular
97 Alkylation, DNA Alkylation, DNA Molecular
103 Activation, Ecdysone receptor Activation, EcR Molecular
105 Inhibition, ECT complexes of the respiratory chain Inhibition, ECT complexes of the respiratory chain
106 Reduction, Eggshell thickness Reduction, Eggshell thickness Tissue
110 Impairment, Endothelial network Impairment, Endothelial network Molecular
111 Agonism, Estrogen receptor Agonism, Estrogen receptor Molecular
112 Antagonism, Estrogen receptor Antagonism, Estrogen receptor Molecular
115 Increase, FA Influx Increase, FA Influx Cellular
116 Activation, FAS Activation, FAS Molecular
118 Formation, Formation of hemoglobin adducts Formation, Formation of hemoglobin adducts Cellular
119 N/A, Gap N/A, Gap Tissue
122 Activation, Glucocorticoid Receptor Activation, Glucocorticoid Receptor Molecular
129 Reduction, Gonadotropins, circulating concentrations Reduction, Gonadotropins, circulating concentrations Organ
130 Depletion, GSH Depletion, GSH Cellular
131 Down Regulation, Gulcose-6-phosphate dehydrogenase Down Regulation, Gulcose-6-phosphate dehydrogenase Cellular
134 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Cellular
135 Increase, Hepatic transport of parent T4 Increase, Hepatic transport of parent T4
136 Up Regulation, Hepatic transporter gene expression Up Regulation, Hepatic transporter gene expression
139 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects Tissue
140 Decreased, HSD17B10 expression Decreased, HSD17B10 expression Cellular
142 Hyperplasia, Hyperplasia Hyperplasia, Hyperplasia Tissue
145 Induction, IKB inhibitory protein Induction, IKB inhibitory protein Cellular
147 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Cellular
149 Increase, Inflammation Increase, Inflammation Cellular
151 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Molecular
152 Suppression, Inflammatory cytokines Suppression, Inflammatory cytokines Individual
155 N/A, Insufficient or incorrect DNA repair N/A, Insufficient or incorrect DNA repair Cellular
158 N/A, Interferences with SH-/selen-proteins N/A, Interferences with SH-/selen-proteins Cellular
161 Increase, Liver and splenic hemosiderosis Increase, Liver and splenic hemosiderosis Organ
164 Induction, Liver “Dysfunctional” Changes by CGA 330050 Induction, Liver “Dysfunctional” Changes by CGA 330050 Organ
165 Activation, Long term AHR receptor driven direct and indirect gene expression changes Activation, Long term AHR receptor driven direct and indirect gene expression changes Cellular
166 Decreased, Long-term potentiation (LTP) Decreased, Long-term potentiation (LTP) Organ
167 Activation, LXR Activation, LXR Molecular
168 Decreased, Lymphocytes Decreased, Lymphocytes Individual
169 Disruption, Membrane integrity Disruption, Membrane integrity Cellular
173 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number Organ
176 Damaging, Mitochondria Damaging, Mitochondria Cellular
177 N/A, Mitochondrial dysfunction 1 N/A, Mitochondrial dysfunction 1 Cellular
178 Disruption, Mitochondrial electron transport chain Disruption, Mitochondrial electron transport chain Cellular
179 Decreased, Mitochondrial fatty acid beta-oxidation Decreased, Mitochondrial fatty acid beta-oxidation Molecular
183 Abnormal, Morphogenesis Abnormal, Morphogenesis
185 Increase, Mutations Increase, Mutations Molecular
186 Altered, Neuroanatomy Altered, Neuroanatomy Organ
188 N/A, Neuroinflammation N/A, Neuroinflammation Tissue
191 N/A, Neuronal dysfunction N/A, Neuronal dysfunction Cellular
192 Altered, Neurophysiology Altered, Neurophysiology Organ
193 Decreased, Nitric Oxide Decreased, Nitric Oxide Cellular
195 Inhibition, NMDARs Inhibition, NMDARs Molecular
201 Binding of antagonist, NMDA receptors Binding of antagonist, NMDA receptors Molecular
202 Inhibition, Nuclear factor kappa B (NF-kB) Inhibition, Nuclear factor kappa B (NF-kB) Molecular
209 Increase, Oxidative Stress Increase, Oxidative Stress Cellular
210 N/A, Oxidative stress N/A, Oxidative stress Cellular
211 Propagation, Oxidative stress Propagation, Oxidative stress Molecular
213 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin Molecular
214 Bile accumulation, Pathological condition Bile accumulation, Pathological condition Cellular
216 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Cellular
219 Reduction, Plasma 17beta-estradiol concentrations Reduction, Plasma 17beta-estradiol concentrations Individual
220 Increase, Plasma vitellogenin concentrations Increase, Plasma vitellogenin concentrations Organ
221 Reduction, Plasma vitellogenin concentrations Reduction, Plasma vitellogenin concentrations Organ
222 Elimination of (high doses), Posterior cardinal vein Elimination of (high doses), Posterior cardinal vein
227 Activation, PPARα Activation, PPARα Molecular
228 Activation, PPARγ Activation, PPARγ Molecular
231 Decreased, PPAR-alpha activation Decreased, PPAR-alpha activation Molecular
232 Decreased, PPAR-beta activation Decreased, PPAR-beta activation Molecular
233 Decreased, PPAR-gamma activation Decreased, PPAR-gamma activation Molecular
234 Activation, PPARα & PPARγ Activation, PPARα & PPARγ Molecular
238 Induction, Pre-mature molting Induction, Pre-mature molting
239 Activation, Pregnane-X receptor, NR1l2 Activation, Pregnane-X receptor, NR1l2 Molecular
240 Feminisation or incomplete development, Primary and accessory male sex organs Feminisation or incomplete development, Primary and accessory male sex organs Organ
243 Reduction, Prostaglandin E2 concentration Reduction, Prostaglandin E2 concentration Tissue
244 Alkylation, Protein Alkylation, Protein Molecular
245 Activation, PXR/SXR Activation, PXR/SXR Molecular
246 Increase, RBC congestion in liver Increase, RBC congestion in liver Organ
249 Production, Reactive oxygen species Production, Reactive oxygen species Tissue
250 Damaging, Red blood cells; hemolysis Damaging, Red blood cells; hemolysis Cellular
252 Increase, Renal pathology due to VTG deposition Increase, Renal pathology due to VTG deposition Organ
253 N/A, Reproductive failure N/A, Reproductive failure Individual
257 Increased, ROS production Increased, ROS production Cellular
258 Activation, SCD-1 Activation, SCD-1 Molecular
259 Decrease, Serum thyroxine (T4) Decrease, Serum thyroxine (T4)
261 Binding, SH-/selen-proteins Binding, SH-/selen-proteins Molecular
264 Activation, SREBP-1c Activation, SREBP-1c Molecular
265 Activation, Stellate cells Activation, Stellate cells Cellular
266 Decrease, Steroidogenic acute regulatory protein (STAR) Decrease, Steroidogenic acute regulatory protein (STAR) Cellular
267 Damage, Structure of the cochlea Damage, Structure of the cochlea
269 Induction, Sustained Cell Proliferation Induction, Sustained Cell Proliferation Cellular
270 Induction, Sustained Hepatotoxicity Induction, Sustained Hepatotoxicity Individual
272 Activation/Proliferation, T-cells Activation/Proliferation, T-cells Organ
274 Reduction, Testosterone synthesis by ovarian theca cells Reduction, Testosterone synthesis by ovarian theca cells Cellular
276 Up Regulation, TGFbeta1 expression Up Regulation, TGFbeta1 expression Cellular
277 Decrease of thyroid hormone synthesis TH synthesis, Decreased Cellular
279 Thyroperoxidase, Inhibition Thyroperoxidase, Inhibition Molecular
280 Decrease of thyroxine (T4) in neuronal tissue T4 in neuronal tissue, Decreased Organ
281 Decrease of thyroxine (T4) in serum T4 in serum, Decreased Tissue
283 Decrease, Tissue thyroid hormone concentration Decrease, Tissue thyroid hormone concentration
284 Decrease, TR-regulated cochlear proteins Decrease, TR-regulated cochlear proteins
285 Reduction, Vitellogenin synthesis in liver Reduction, Vitellogenin synthesis in liver Tissue
286 Decreased, Transcription of genes by AR Decreased, Transcription of genes by AR Cellular
288 Activation of specific nuclear receptors, Transcriptional change Activation of specific nuclear receptors, Transcriptional change Cellular
289 Decrease, Translocator protein (TSPO) Decrease, Translocator protein (TSPO) Cellular
291 Accumulation, Triglyceride Accumulation, Triglyceride Cellular
294 N/A, Unknown N/A, Unknown Molecular
295 Induction, Upregulation of glucuronyltransferase activity Induction, Upregulation of glucuronyltransferase activity Molecular
298 Insufficiency, Vascular Insufficiency, Vascular Molecular
301 Binding, VEGF-A Binding, VEGF-A
302 Production, VEGF-A Production, VEGF-A
304 Decreased, VegfR2 Decreased, VegfR2
305 Inhibition, VegfR2 Inhibition, VegfR2 Molecular
307 Increase, Vitellogenin synthesis in liver Increase, Vitellogenin synthesis in liver Tissue
309 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Cellular
310 Alteration, Wnt pathway Alteration, Wnt pathway Cellular
312 N/A, Allergic contact dermatitis on challenge N/A, Allergic contact dermatitis on challenge Individual
313 Increase, Allergic Respiratory Hypersensitivity Response Increase, Allergic Respiratory Hypersensitivity Response Organ
315 Decreased, Body length Decreased, Body length
317 Altered, Cardiovascular development/function Altered, Cardiovascular development/function Organ
319 Loss, Cochlear function Loss, Cochlear function Organ
320 Increase, Curved body axis Increase, Curved body axis
321 N/A, Cyanosis occurs N/A, Cyanosis occurs Individual
323 Increased, Disease susceptibility Increased, Disease susceptibility Individual
325 N/A, Embryotoxicity N/A, Embryotoxicity Individual
327 Accumulation, Fatty acid Accumulation, Fatty acid Organ
328 Reduction, Fecundity Reduction, Fecundity
330 Decreased, Fertility Decreased, Fertility Individual
331 Decreased, Fetal birth weight Decreased, Fetal birth weight
332 Increased, Functional deficits Increased, Functional deficits
334 Promotion, Hepatocelluar carcinoma Promotion, Hepatocelluar carcinoma Individual
336 Increase, Heritable mutations in offspring Increase, Heritable mutations in offspring Individual
337 N/A, Impairment of reproductive capacity N/A, Impairment of reproductive capacity Individual
339 Altered, Larval development Altered, Larval development Individual
341 Impairment, Learning and memory Impairment, Learning and memory Individual
342 Increased, Lethality Increased, Lethality
344 N/A, Liver fibrosis N/A, Liver fibrosis Organ
345 N/A, Liver Steatosis N/A, Liver Steatosis Organ
346 Undefined, Liver Steatosis Undefined, Liver Steatosis Organ
347 Formation, Liver tumor Formation, Liver tumor Individual
348 Malformation, Male reproductive tract Malformation, Male reproductive tract Organ
350 Increase, Mortality Increase, Mortality Individual
351 Increased, Mortality Increased, Mortality Population
352 N/A, Neurodegeneration N/A, Neurodegeneration Tissue
356 Increased, Oxidative damage Increased, Oxidative damage Individual
357 Cholestasis, Pathology Cholestasis, Pathology Individual
358 Increase, Pericardial edema Increase, Pericardial edema Organ
360 Decrease, Population trajectory Decrease, Population trajectory Individual
361 Decline, Population Decline, Population Population
363 Altered, Reproductive behaviour Altered, Reproductive behaviour Individual
364 Impaired development of, Reproductive organs Impaired development of, Reproductive organs Individual
366 Increased, Structural malformations Increased, Structural malformations
369 Uroporphyria Uroporphyria Individual
373 Formation, Pro-mutagenic DNA Adducts Formation, Pro-mutagenic DNA Adducts Molecular
376 Increased, Induced Mutations in Critical Genes Increased, Induced Mutations in Critical Genes Cellular
377 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered Hepatic Foci (AHF)) Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
378 Tumorigenesis, Hepatocellular carcinoma Tumorigenesis, Hepatocellular carcinoma Individual
380 Activation, Pre-MIE: Metabolism of AFB1 Activation, Pre-MIE: Metabolism of AFB1 Molecular
381 Reduced levels of BDNF BDNF, Reduced Molecular
382 Aberrant, Dendritic morphology Aberrant, Dendritic morphology Cellular
383 Reduced, Presynaptic release of glutamate Reduced, Presynaptic release of glutamate Molecular
384 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
385 Decrease of synaptogenesis Synaptogenesis, Decreased Cellular
386 Decrease of neuronal network function Neuronal network function, Decreased Organ
387 Binding of agonist, NMDARs Binding of agonist, NMDARs Molecular
388 Overactivation, NMDARs Overactivation, NMDARs Molecular
389 Increased, Intracellular Calcium overload Increased, Intracellular Calcium overload Cellular
396 Covalent Binding, Protein Covalent Binding, Protein Molecular
397 Response, Keratinocytes Response, Keratinocytes Cellular
398 Activation, Dendritic Cells Activation, Dendritic Cells Cellular
401 Increase, Biliary excretion TH glucuronide Increase, Biliary excretion TH glucuronide Organ
402 Cognitive Function, Decreased Cognitive Function, Decreased Individual
403 Suppression, Immune system Suppression, Immune system Individual
405 irregularities, ovarian cycle irregularities, ovarian cycle Individual
406 impaired, Fertility impaired, Fertility Individual
408 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) reduction in ovarian granulosa cells, Aromatase (Cyp19a1) Cellular
409 Metabolism of AFB1, Production of Reactive Electrophiles Metabolism of AFB1, Production of Reactive Electrophiles Molecular
413 Reduction, Testosterone synthesis in Leydig cells Reduction, Testosterone synthesis in Leydig cells Cellular
414 Increase, Luteinizing hormone (LH) Increase, Luteinizing hormone (LH) Cellular
415 Hyperplasia, Leydig cell Hyperplasia, Leydig cell Organ
416 Increase proliferation, Leydig cell Increase proliferation, Leydig cell Cellular
417 skewed, sex ratio skewed, sex ratio Population
418 Increased, Vitellogenin synthesis Increased, Vitellogenin synthesis Cellular
419 Increased, renal vitellogenin deposition Increased, renal vitellogenin deposition Organ
421 Increased, glomerular rupture and renal hemorrhaging Increased, glomerular rupture and renal hemorrhaging Organ
422 Increased, nephropathy Increased, nephropathy Individual
423 Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foci Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foc
424 Inhibition, Na+/I- symporter (NIS) Inhibition, Na+/I- symporter (NIS) Molecular
425 Decrease of Thyroidal iodide Thyroidal Iodide, Decreased Cellular
426 Decreased, Thyroxine (T4) in serum Decreased, Thyroxine (T4) in serum Tissue
427 Down Regulation, K-Cl co-transporter 2 (KCC2) Down Regulation, K-Cl co-transporter 2 (KCC2) Cellular
428 Delay, Developmental GABA shift Delay, Developmental GABA shift Cellular
429 Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alteration of cellular growth homeostasis Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alterati
442 Decreased, Population trajectory Decreased, Population trajectory Population
444 Increased, Atrioventricular block and bradycardia Increased, Atrioventricular block and bradycardia Organ
445 Increased, Respiratory distress/arrest Increased, Respiratory distress/arrest Organ
446 Reduction, testosterone level Reduction, testosterone level Tissue
447 Reduction, Cholesterol transport in mitochondria Reduction, Cholesterol transport in mitochondria Cellular
450 Suppression, VLDL secretion Suppression, VLDL secretion Cellular
451 Inhibition, Mitochondrial fatty acid beta-oxidation Inhibition, Mitochondrial fatty acid beta-oxidation Molecular
454 Increased, Triglyceride formation Increased, Triglyceride formation Cellular
455 Accumulation, Liver lipid Accumulation, Liver lipid Organ
456 Suppression, Constitutive androstane receptor, NR1l3 Suppression, Constitutive androstane receptor, NR1l3 Molecular
457 Activation, SREBF1 Activation, SREBF1 Molecular
458 Increased, De Novo FA synthesis Increased, De Novo FA synthesis Cellular
459 Increased, Liver Steatosis Increased, Liver Steatosis Organ
460 Increased, Fatty acid uptake Increased, Fatty acid uptake Cellular
461 Suppression, HNF4alpha Suppression, HNF4alpha Molecular
462 Up Regulation, SCD-1 Up Regulation, SCD-1 Molecular
463 Up Regulation, FAS Up Regulation, FAS Molecular
464 Increased, SCD-1 Increased, SCD-1 Molecular
465 Increased, FA Influx Increased, FA Influx Cellular
466 Up Regulation, LDLR (low density lipoprotein receptor) Up Regulation, LDLR (low density lipoprotein receptor) Molecular
467 Increased, LDL uptake Increased, LDL uptake Cellular
468 Inhibition, PPAR alpha Inhibition, PPAR alpha Molecular
470 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Molecular
471 Inhibition, FoxA2 Inhibition, FoxA2 Molecular
472 Down Regulation, CPT1A Down Regulation, CPT1A Molecular
474 Down Regulation, HMGCS2 Down Regulation, HMGCS2 Molecular
475 Increased, Hepatic Triglycerides Increased, Hepatic Triglycerides Tissue
476 Accumulation, Hepatic FA Accumulation, Hepatic FA Organ
477 Decreased, Ketogenesis Decreased, Ketogenesis Cellular
478 Activation, NRF2 Activation, NRF2 Molecular
479 Activation, NR1H4 Activation, NR1H4 Molecular
480 Activation, SHP Activation, SHP Molecular
482 Decreased, DHB4/HSD17B4 Decreased, DHB4/HSD17B4 Molecular
483 Activation, LXR alpha Activation, LXR alpha Molecular
484 Activation, AKT2 Activation, AKT2 Molecular
485 Activtation, SREBP-1c Activtation, SREBP-1c Molecular
486 systemic inflammation leading to hepatic steatosis inflammation Organ
488 Decrease, Ovulation Decrease, Ovulation Tissue
491 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Organ
493 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Molecular
494 Activation of specific nuclear receptors, Glucocorticoid Receptor Agonist Activation of specific nuclear receptors, Glucocorticoid Receptor Agonist Molecular
495 Abnormal steroidogenic gene expression, Decreased testosterone by the Leydig cell Abnormal steroidogenic gene expression, Decreased testosterone by the Leydig cell Cellular
496 Increased Apoptosis, Decreased Leydig cells Increased Apoptosis, Decreased Leydig cells Cellular
497 Decreased Sperm Number, Reduced Fertility Decreased Sperm Number, Reduced Fertility Individual
498 Accelerated Epididymal Sperm Transit, Reduced Fertility Accelerated Epididymal Sperm Transit, Reduced Fertility Individual
499 Abnormal Sperm Maturation, Reduced Fertility Abnormal Sperm Maturation, Reduced Fertility Individual
505 Decreased sperm quantity / quality in the adult, Decreased fertility Decreased sperm quantity / quality in the adult, Decreased fertility Individual
520 Decreased sperm quantity or quality in the adult, Decreased fertility Decreased sperm quantity or quality in the adult, Decreased fertility Individual
525 Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Cellular
526 Inhibition, Inhibition of Dopamine-beta-hydroxylase Inhibition, Inhibition of Dopamine-beta-hydroxylase Molecular
527 Decreased, Decreased fecundity Decreased, Decreased fecundity Individual
528 Decreased, Synthesis of NE Decreased, Synthesis of NE Cellular
529 Decreased, GnRH cfos activity Decreased, GnRH cfos activity Molecular
530 Decreased, GnRH pulsatility/release Decreased, GnRH pulsatility/release Cellular
531 Decreased, LH Surge Decreased, LH Surge Cellular
532 Delayed, Ovulation Delayed, Ovulation Individual
533 Decreased, Cortical granule release/distribution upon fertilization Decreased, Cortical granule release/distribution upon fertilization Cellular
534 Altered, Formation of cortical envelope Altered, Formation of cortical envelope Cellular
535 Abnormal, Sperm penetration (polyspermy) Abnormal, Sperm penetration (polyspermy) Cellular
536 Altered, Chromosome number (polyploid) zygote Altered, Chromosome number (polyploid) zygote Cellular
540 Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Organ
541 Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
543 Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult test Individual
559 Activation, Nicotinic acetylcholine receptor Activation, Nicotinic acetylcholine receptor Molecular
560 Abnormal, Foraging activity and behavior Abnormal, Foraging activity and behavior Individual
561 Reduced, Food storage Reduced, Food storage Population
563 Death/Failure, Colony Death/Failure, Colony Population
564 Abnormal, Roll change within caste Abnormal, Roll change within caste Population
565 Reduced, Brood care Reduced, Brood care Population
566 impaired, Larval development impaired, Larval development Population
568 impaired, Hive thermoregulation impaired, Hive thermoregulation Population
570 Accumulation, Damaged mitochondrial DNA Accumulation, Damaged mitochondrial DNA Cellular
571 Accelerated, Aging Accelerated, Aging Individual
572 Decrease, Number of worker bees Decrease, Number of worker bees Population
573 Increase, Energetic demands and therefore metabolic stress Increase, Energetic demands and therefore metabolic stress Individual
574 Increased, Appetite and hunger Increased, Appetite and hunger Individual
576 Increased, Viral susceptibility Increased, Viral susceptibility Individual
577 impaired, Development impaired, Development Individual
578 Decreased, Glucose oxidase enzyme activity Decreased, Glucose oxidase enzyme activity Molecular
579 Decreased, Hydrogen peroxide production Decreased, Hydrogen peroxide production Molecular
580 Reduced, Antiseptic incorporated in food Reduced, Antiseptic incorporated in food Population
583 impaired, Thoracic shivering impaired, Thoracic shivering Individual
584 Inhibition, sodium channel Inhibition, sodium channel Molecular
585 Decreased, Sodium conductance 1 Decreased, Sodium conductance 1 Cellular
586 Reduced, swimming speed Reduced, swimming speed Individual
587 Reduced, feeding 1 Reduced, feeding 1 Individual
588 Increased, predation Increased, predation Population
590 N/A, hypoxia N/A, hypoxia Tissue
591 Increased, amputations Increased, amputations Individual
592 Reduced, survival Reduced, survival Population
593 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Molecular
598 modulation, sodium channel modulation, sodium channel Molecular
599 prolonged, Depolarization of neuronal membrane prolonged, Depolarization of neuronal membrane Cellular
600 Overactivation, Neuronotransmitter release Overactivation, Neuronotransmitter release Molecular
601 Overactivation, muscle contraction Overactivation, muscle contraction Tissue
602 Increased, Ataxia, paralysis, or hyperactivity Increased, Ataxia, paralysis, or hyperactivity Organ
613 Occurrence, Epileptic seizure Occurrence, Epileptic seizure Individual
616 Occurrence, A paroxysmal depolarizing shift Occurrence, A paroxysmal depolarizing shift Tissue
618 Decreased, Neuronal network function in adult brain Decreased, Neuronal network function in adult brain Organ
619 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Molecular
620 Increased, serotonin (5-HT) 1 1 Increased, serotonin (5-HT) 1 Molecular
621 Increase, cilia movement Increase, cilia movement Tissue
622 Increased, locomotion Increased, locomotion Individual
623 Increase, predation Increase, predation Population
624 Increased, foot detachment Increased, foot detachment Individual
625 Increased, muscular waves in foot Increased, muscular waves in foot Organ
626 Increased, serotonin (5-HT) Increased, serotonin (5-HT) Cellular
627 Decreased, anxiety Decreased, anxiety Individual
629 Decreased, sheltering Decreased, sheltering Individual
633 Decrease, histaminergic neuron excitation Decrease, histaminergic neuron excitation Cellular
634 N/A, sedation N/A, sedation Individual
635 Decreased, locomotion Decreased, locomotion Individual
636 Decreased, survival Decreased, survival Population
637 impaired, Learning and memory impaired, Learning and memory Individual
638 Antagonism, Histamine Receptor (H2) Antagonism, Histamine Receptor (H2) Molecular
640 Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Molecular
642 Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Molecular
643 Decreased Cholesterol, Decreased Uptake of Lipoproteins Decreased Cholesterol, Decreased Uptake of Lipoproteins Molecular
644 Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membra Molecular
645 Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Cellular
646 Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Organ
647 Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cell Cellular
648 Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Tissue
649 Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Tissue
650 Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Molecular
651 Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testostero Cellular
652 Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig Cellular
653 Decreased testosterone by the fetal Leydig cells, Increased corticosterone Decreased testosterone by the fetal Leydig cells, Increased corticosterone Cellular
654 Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid recept Cellular
655 Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Cellular
656 Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
657 Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
658 Decreased testosterone by the fetal Leydig cells, Increased estradiol Decreased testosterone by the fetal Leydig cells, Increased estradiol Cellular
659 Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Cellular
660 decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
661 Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Molecular
662 Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Molecular
663 Desensitization, Nicotinic acetylcholine receptor Desensitization, Nicotinic acetylcholine receptor Molecular
664 Overwhelmed, Mitochondrial DNA repair mechanisms Overwhelmed, Mitochondrial DNA repair mechanisms Cellular
667 Binding at picrotoxin site, iGABAR chloride channel Binding at picrotoxin site, iGABAR chloride channel Molecular
669 Reduction, Neuronal synaptic inhibition Reduction, Neuronal synaptic inhibition Cellular
671 Reduced, Prostaglandin F2alpha concentration, plasma Reduced, Prostaglandin F2alpha concentration, plasma Individual
672 Reduced, Prostaglandin F2alpha synthesis, ovary Reduced, Prostaglandin F2alpha synthesis, ovary Organ
673 Reduced, Spawning behavior Reduced, Spawning behavior Individual
674 Reduced, Ability to attract spawning mates Reduced, Ability to attract spawning mates Individual
675 Reduced, Reproductive Success Reduced, Reproductive Success Individual
678 Reduced, Pheromone release Reduced, Pheromone release Individual
679 Decline, Population trajectory Decline, Population trajectory Population
681 Decreased, Prostaglandin F2alpha synthesis, ovary Decreased, Prostaglandin F2alpha synthesis, ovary Organ
682 Generation, Amplified excitatory postsynaptic potential (EPSP) Generation, Amplified excitatory postsynaptic potential (EPSP) Cellular
685 Reduced, Prostaglandins, ovary Reduced, Prostaglandins, ovary Organ
686 Declining, Population trajectory Declining, Population trajectory Population
687 Reduced, Prostaglandin E2 concentration, hypothalamus Reduced, Prostaglandin E2 concentration, hypothalamus Tissue
689 Reduced, Gonadotropin releasing hormone, hypothalamus Reduced, Gonadotropin releasing hormone, hypothalamus Tissue
690 Reduced, Luteinizing hormone (LH), plasma Reduced, Luteinizing hormone (LH), plasma Tissue
691 Reduced, Maturation inducing steroid, plasma Reduced, Maturation inducing steroid, plasma Tissue
692 Reduced, Maturation inducing steroid receptor signalling, oocyte Reduced, Maturation inducing steroid receptor signalling, oocyte Tissue
693 Increased, cyclic adenosine monophosphate Increased, cyclic adenosine monophosphate Tissue
694 Reduced, Meiotic prophase I/metaphase I transition, oocyte Reduced, Meiotic prophase I/metaphase I transition, oocyte Cellular
695 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Molecular
696 Increased, Chromosome misseggregation Increased, Chromosome misseggregation Cellular
697 impaired, ion channels impaired, ion channels Cellular
698 Altered, Action Potential Altered, Action Potential Cellular
699 Increased, cardiac arrthymia Increased, cardiac arrthymia Organ
708 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Tissue
709 Increase, Cytotoxicity (renal tubular cell) Increase, Cytotoxicity (renal tubular cell) Cellular
710 Increase, Regenerative cell proliferation (tubular epithelial cells) Increase, Regenerative cell proliferation (tubular epithelial cells) Cellular
713 Increase, Adenomas/carcinomas (renal tubular) Increase, Adenomas/carcinomas (renal tubular) Tissue
714 Increased, Binding of chemicals to 2u (serum) Increased, Binding of chemicals to 2u (serum) Molecular
715 Activation, Constitutive androstane receptor Activation, Constitutive androstane receptor Molecular
716 Increase, Mitogenic cell proliferation (hepatocytes) Increase, Mitogenic cell proliferation (hepatocytes) Cellular
718 Binding, Tubulin Binding, Tubulin Molecular
719 Increase, Adenomas/carcinomas (hepatocellular) Increase, Adenomas/carcinomas (hepatocellular) Tissue
720 Depolymerization, Microtubule Depolymerization, Microtubule Molecular
721 Disorganization, Spindle Disorganization, Spindle Cellular
723 Altered, Chromosome number Altered, Chromosome number Cellular
724 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Cellular
726 Increased, Induction of pyruvate dehydrogenase (PDH) Increased, Induction of pyruvate dehydrogenase (PDH) Molecular
728 Increase, Aneuploid offspring Increase, Aneuploid offspring Individual
733 Increase, Necrosis (terminal bronchiolar cells) Increase, Necrosis (terminal bronchiolar cells) Cellular
734 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Cellular
735 Increase, Hyperplasia (terminal bronchiolar cells) Increase, Hyperplasia (terminal bronchiolar cells) Cellular
736 Increase, Adenomas/carcinomas (bronchioloalveolar) Increase, Adenomas/carcinomas (bronchioloalveolar) Tissue
737 Decreased, Uptake of inorganic iodide Decreased, Uptake of inorganic iodide Cellular
739 Increase, Hypertrophy and proliferation (follicular cell) Increase, Hypertrophy and proliferation (follicular cell) Cellular
740 Increase, Hyperplasia (follicular cells) Increase, Hyperplasia (follicular cells) Cellular
741 Increase, Adenomas/carcinomas (follicular cell) Increase, Adenomas/carcinomas (follicular cell) Tissue
742 Decreased, Androgen receptor activity Decreased, Androgen receptor activity Molecular
743 Decreased, Testosterone binding to androgen receptor (hypothalamus) Decreased, Testosterone binding to androgen receptor (hypothalamus) Molecular
744 Increase, Hyperplasia (Leydig cells) Increase, Hyperplasia (Leydig cells) Cellular
745 Increase, Leydig cell tumors Increase, Leydig cell tumors Cellular
746 Increase, Dopaminergic activity Increase, Dopaminergic activity Cellular
747 Decreased, Prolactin Decreased, Prolactin Tissue
748 Increased, Estrogen receptor (ER) activity Increased, Estrogen receptor (ER) activity Molecular
749 Decreased, Progesterone from corpus luteum Decreased, Progesterone from corpus luteum Tissue
752 Altered, Meiotic chromosome dynamics Altered, Meiotic chromosome dynamics Cellular
753 Increase, Thyroid-stimulating hormone (TSH) Increase, Thyroid-stimulating hormone (TSH) Tissue
754 Increased, Luteinizing hormone (LH) Increased, Luteinizing hormone (LH) Tissue
756 Hippocampal gene expression, Altered Hippocampal gene expression, Altered Tissue
757 Hippocampal anatomy, Altered Hippocampal anatomy, Altered Tissue
758 Hippocampal Physiology, Altered Hippocampal Physiology, Altered Tissue
759 Increased, Kidney Failure Increased, Kidney Failure Individual
760 Activation, Glutamate-gated chloride channel Activation, Glutamate-gated chloride channel Molecular
761 Increased, Chloride conductance Increased, Chloride conductance Cellular
762 Activation, ionotropic GABA Receptor chloride channel Activation, ionotropic GABA Receptor chloride channel Molecular
763 hyperpolarisation, neuron hyperpolarisation, neuron Cellular
764 N/A, Ataxia, paralysis, or hyperactivity N/A, Ataxia, paralysis, or hyperactivity Organ
765 Decreased, population 1 Decreased, population 1 Population
766 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Molecular
767 Increase, Hyperplasia (renal tubular cells) Increase, Hyperplasia (renal tubular cells) Cellular
768 Increase, Cytotoxicity Increase, Cytotoxicity Cellular
769 Increase, Oxidative metabolism Increase, Oxidative metabolism Cellular
770 Increase, Cytotoxicity (club cells) Increase, Cytotoxicity (club cells) Cellular
771 Decrease, Serum thyroid hormone (T4/T3) Decrease, Serum thyroid hormone (T4/T3) Tissue
772 Increase, Hyperplasia (glandular epithelial cells of endometrium) Increase, Hyperplasia (glandular epithelial cells of endometrium) Cellular
773 Increase, Endometrial adenocarcinomas Increase, Endometrial adenocarcinomas Tissue
774 Increase, Preneoplastic foci (hepatocytes) Increase, Preneoplastic foci (hepatocytes) Cellular
775 Increased, Plasma tyrosine Increased, Plasma tyrosine Tissue
776 Increase, Cytotoxicity (corneal cells) Increase, Cytotoxicity (corneal cells) Cellular
777 Increase, Inflammation (corneal cells) Increase, Inflammation (corneal cells) Cellular
778 Increase, Regenerative cell proliferation (corneal cells) Increase, Regenerative cell proliferation (corneal cells) Cellular
779 Increase, Papillomas/carcinomas (squamous cells) Increase, Papillomas/carcinomas (squamous cells) Cellular
780 Increase, Cytotoxicity (epithelial cells) Increase, Cytotoxicity (epithelial cells) Cellular
781 Increase, Regenerative cell proliferation (forestomach epithelial cells) Increase, Regenerative cell proliferation (forestomach epithelial cells) Cellular
782 Increase, Hyperplasia (forestomach epithelial cells) Increase, Hyperplasia (forestomach epithelial cells) Cellular
783 Increase, Cytotoxicity (tubular epithelial cells) Increase, Cytotoxicity (tubular epithelial cells) Cellular
784 Increase, Hyperplasia (tubular epithelial cells) Increase, Hyperplasia (tubular epithelial cells) Cellular
785 Activation, Androgen receptor Activation, Androgen receptor Molecular
786 Increase, Cytotoxicity (hepatocytes) Increase, Cytotoxicity (hepatocytes) Cellular
787 Increase, Regenerative cell proliferation (hepatocytes) Increase, Regenerative cell proliferation (hepatocytes) Cellular
788 Decrease, Incorporation of active iodide into iodotyrosines Decrease, Incorporation of active iodide into iodotyrosines Cellular
790 Inhibition, 5α-reductase activity Inhibition, 5α-reductase activity Cellular
791 Increased, Leutinizing hormone (LH) Increased, Leutinizing hormone (LH) Tissue
792 Decrease, Bioactivation of testosterone Decrease, Bioactivation of testosterone Tissue
793 Increase, Urinary bladder calculi Increase, Urinary bladder calculi Organ
794 Increase, Cytotoxicity (urothelial cells) Increase, Cytotoxicity (urothelial cells) Cellular
795 Increase, Regenerative cell proliferation (urothelial cells) Increase, Regenerative cell proliferation (urothelial cells) Cellular
796 Increase, Hyperplasia (urothelial) Increase, Hyperplasia (urothelial) Cellular
797 Increase, Adenomas/carcinomas (urothelial) Increase, Adenomas/carcinomas (urothelial) Tissue
798 Inhibition, Prolyl hydroxylases Inhibition, Prolyl hydroxylases Cellular
799 Increased, HIF-1 heterodimer Increased, HIF-1 heterodimer Cellular
800 Decreased, Aromatase (Cyp19a1) mRNA Decreased, Aromatase (Cyp19a1) mRNA Cellular
801 modulation, Unknown modulation, Unknown Molecular
802 Increased, HIF-1 alpha transcription Increased, HIF-1 alpha transcription Cellular
804 Inhibition, HMG-CoA reductase Inhibition, HMG-CoA reductase Cellular
805 Decreased, mevalonate Decreased, mevalonate Cellular
807 Decreased, cholesterol Decreased, cholesterol Cellular
808 Decreased, Testosterone Decreased, Testosterone Individual
809 malformed, Male reproductive tract malformed, Male reproductive tract Individual
813 Increased, Serum creatinine Increased, Serum creatinine Organ
814 Occurrence, Kidney toxicity Occurrence, Kidney toxicity Organ
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) Occurrence, Cytoplasmic vacuolization (Renal tubule) Organ
819 Decreased, Glomerular filtration Decreased, Glomerular filtration Tissue
820 Decreased, Renal plasma flow Decreased, Renal plasma flow Tissue
821 Decreased, Sodium reabsorption Decreased, Sodium reabsorption Organ
823 Occurrence, Cystic dilatation (renal tubule) Occurrence, Cystic dilatation (renal tubule) Organ
824 Occurrence, Cytoplasmic vacuolization (podocyte) Occurrence, Cytoplasmic vacuolization (podocyte) Organ
825 Decreased, Renal ability to dilute urine Decreased, Renal ability to dilute urine Organ
826 Activation, Keratinocytes Activation, Keratinocytes Cellular
827 sensitisation, skin sensitisation, skin Organ
828 Inhibition, Phospholipase A Inhibition, Phospholipase A Molecular
829 Damage, Lipid bilayer Damage, Lipid bilayer Cellular
831 Disturbance, Lysosomal function Disturbance, Lysosomal function Cellular
832 Injury, Mitochondria Injury, Mitochondria Cellular
833 Occurrence, Cytoplasmic vacuolization (hepatocyte) Occurrence, Cytoplasmic vacuolization (hepatocyte) Cellular
835 Occurrence, Ballooning degeneration (hepatocyte) Occurrence, Ballooning degeneration (hepatocyte) Cellular
836 Occurrence, Cytoplasmic vacuolization (Bile duct cell) Occurrence, Cytoplasmic vacuolization (Bile duct cell) Cellular
837 Occurrence, Cytoplasmic vacuolization (kupffer cell) Occurrence, Cytoplasmic vacuolization (kupffer cell) Cellular
838 Induction, Microvesicular fat Induction, Microvesicular fat Tissue
839 Formation, Mallory body Formation, Mallory body Cellular
840 Formation, Liver fibrosis Formation, Liver fibrosis Tissue
844 Oxidation, Uroporphyrinogen Oxidation, Uroporphyrinogen Cellular
845 Inhibition, UROD Inhibition, UROD Molecular
846 Accumulation, Highly carboxylated porphyrins Accumulation, Highly carboxylated porphyrins Organ
848 Decreased, Binding of NE to NE receptors on GnRH neurons Decreased, Binding of NE to NE receptors on GnRH neurons Cellular
849 Inhibition, Antgonism of NE receptor Inhibition, Antgonism of NE receptor Molecular
850 Induction, CYP1A2/CYP1A5 Induction, CYP1A2/CYP1A5 Molecular
851 Decrease of GABAergic interneurons GABAergic interneurons, Decreased Cellular
853 Changes/Inhibition, Cellular Homeostasis and Apoptosis Changes/Inhibition, Cellular Homeostasis and Apoptosis Cellular
854 Alterations, Cellular proliferation / hyperplasia Alterations, Cellular proliferation / hyperplasia Tissue
856 Formation, Hepatocellular and Bile duct tumors Formation, Hepatocellular and Bile duct tumors Organ
857 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Molecular
858 Decreased, PPARalpha transactivation of gene expression Decreased, PPARalpha transactivation of gene expression Molecular
859 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
860 Decreased, Mitochondrial Fatty Acid Beta Oxidation Decreased, Mitochondrial Fatty Acid Beta Oxidation Molecular
861 Decreased, Ketogenesis (production of ketone bodies) Decreased, Ketogenesis (production of ketone bodies) Cellular
862 Not Increased, Circulating Ketone Bodies Not Increased, Circulating Ketone Bodies Tissue
863 Increased, Catabolism of Muscle Protein Increased, Catabolism of Muscle Protein Organ
864 Decreased, Body Weight Decreased, Body Weight Individual
867 Decrease, Intracellular pH Decrease, Intracellular pH Cellular
868 Increase, Tissue Degeneration, Necrosis & Atrophy Increase, Tissue Degeneration, Necrosis & Atrophy Tissue
869 Increase, Respiratory or Squamous Metaplasia Increase, Respiratory or Squamous Metaplasia Tissue
870 Increase, Cell Proliferation Increase, Cell Proliferation Cellular
872 Increase, Site of Contact Nasal Tumors Increase, Site of Contact Nasal Tumors Organ
875 Binding of agonist, Ionotropic glutamate receptors Binding of agonist, Ionotropic glutamate receptors Molecular
876 Increase, Mutations in Critical Genes Increase, Mutations in Critical Genes Molecular
877 Inhibition, organic anion transporter 1 (OAT1) Inhibition, organic anion transporter 1 (OAT1) Molecular
878 Inhibition, SREBP1c Inhibition, SREBP1c Molecular
879 Activation, MTTP Activation, MTTP Cellular
880 Increased, ApoB100 Increased, ApoB100 Tissue
881 Increased, Triglyceride Increased, Triglyceride Cellular
882 Decreased, De Novo FA synthesis Decreased, De Novo FA synthesis Cellular
885 Increase, Cancer Increase, Cancer Tissue
887 Inhibition, NADH-ubiquinone oxidoreductase (complex I) Inhibition, NADH-ubiquinone oxidoreductase (complex I) Cellular
888 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Molecular
889 impaired, Proteostasis impaired, Proteostasis Cellular
890 Degeneration of dopaminergic neurons of the nigrostriatal pathway Degeneration of dopaminergic neurons of the nigrostriatal pathway Organ
896 Parkinsonian motor deficits Parkinsonian motor deficits Individual
898 Disruption, Lysosome Disruption, Lysosome Cellular
901 Infiltration, Inflammatory cells Infiltration, Inflammatory cells Tissue
902 Inflammation, Liver Inflammation, Liver Organ
907 Infiltration, Inflammatory cytokines Infiltration, Inflammatory cytokines
913 Activation, Epidermal Growth Factor Receptor Activation, Epidermal Growth Factor Receptor
914 Decrease, Apoptosis of ciliated epithelial cells Decrease, Apoptosis of ciliated epithelial cells Cellular
919 Occurrence, Transdifferentiation of ciliated epithelial cells Occurrence, Transdifferentiation of ciliated epithelial cells Cellular
920 Occurrence, Metaplasia of goblet cells Occurrence, Metaplasia of goblet cells Tissue
921 Occurrence, Hyperplasia of goblet cells Goblet cell hyperplasia Tissue
923 Increase, Proliferation of goblet cells Increase, Proliferation of goblet cells Cellular
924 Activation, SP1 Activation, SP1 Molecular
926 Oxidation, Glutathione Oxidation, Glutathione Molecular
927 S-Glutathionylation, eNOS S-Glutathionylation, eNOS Molecular
932 Uncoupling, eNOS Uncoupling, eNOS Cellular
933 Depletion, Nitric Oxide Depletion, Nitric Oxide Cellular
934 Decrease, Tetrahydrobiopterin Decrease, Tetrahydrobiopterin Cellular
935 Decrease, GTPCH-1 Decrease, GTPCH-1 Cellular
937 impaired, Vasodilation impaired, Vasodilation Organ
941 Activation, EGFR Activation, EGFR Molecular
943 Hypersecretion, Mucus Hypersecretion, Mucus Organ
944 dimerization, AHR/ARNT dimerization, AHR/ARNT Molecular
945 reduced dimerization, ARNT/HIF1-alpha reduced dimerization, ARNT/HIF1-alpha Molecular
947 Increase, Embryolethality Increase, Embryolethality Individual
948 reduced production, VEGF reduced production, VEGF Cellular
951 Increase, Vascular Resistance Increase, Vascular Resistance Organ
952 N/A, Hypertension N/A, Hypertension Individual
957 Binding, Transthyretin in serum Binding, Transthyretin in serum Molecular
958 Displacement, Serum thyroxine (T4) from transthyretin Displacement, Serum thyroxine (T4) from transthyretin Molecular
959 Increased, Free serum thyroxine (T4) Increased, Free serum thyroxine (T4) Tissue
960 Increased, Uptake of thyroxine into tissue Increased, Uptake of thyroxine into tissue Cellular
961 Increased, Clearance of thyroxine from tissues Increased, Clearance of thyroxine from tissues Tissue
962 Increase, Mucin production Increase, Mucin production Cellular
964 Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle b Molecular
965 reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic producti Cellular
966 Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulos Tissue
967 Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation de Organ
968 Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces Cellular
969 Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Cellular
970 Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituit Cellular
971 Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required f Individual
972 Decreased fertility, Reduced number of oocytes ovulated Decreased fertility, Reduced number of oocytes ovulated Individual
973 Decrease, Akt/eNOS activity Decrease, Akt/eNOS activity Cellular
974 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12,
975 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12
976 Formation, The binding of FK506 with FKBP12 Formation, The binding of FK506 with FKBP12 Molecular
977 Binding, Binding of calcineurin with FK506-FKBP complexes Binding, Binding of calcineurin with FK506-FKBP complexes
978 Activation, Suppression of NFAT activation and hindrance of nuclear localization Activation, Suppression of NFAT activation and hindrance of nuclear localization Molecular
979 Interference, nuclear localization of NFAT Interference, nuclear localization of NFAT Molecular
980 Inhibition, Calcineurin Activity Inhibition, Calcineurin Activity Molecular
981 Reduction, NFAT complex formation Reduction, NFAT complex formation Cellular
982 Suppression, Suppression in mixed lymphocyte reaction (MLR) Suppression, Suppression in mixed lymphocyte reaction (MLR) Cellular
983 Suppression, Suppression of T-cell dependent antibody response (TDAR) Suppression, Suppression of T-cell dependent antibody response (TDAR) Cellular
984 Impairment, T-cell dependent antibody response Impairment, T-cell dependent antibody response Individual
985 Relief, Relief of atopic dermatitis Relief, Relief of atopic dermatitis Individual
986 Increase, Increased susceptibility to infection Increase, Increased susceptibility to infection Individual
987 , Metaplasia of goblet cells , Metaplasia of goblet cells
988 Reduction, Release of circulating ecdysis triggering hormone Reduction, Release of circulating ETH Tissue
989 Decreased, synthesis and secretion of molting fluid proteases Decreased, synthesis and secretion of molting fluid proteases
990 Induction, Incomplete ecdysis Induction, Incomplete ecdysis Individual
991 Increased, Alterations of food-web structures Increased, Alterations of food-web structures
992 Decreased, Population 2 Decreased, Population 2
993 Reduction, Abdominal muscle contraction Reduction, Abdominal muscle contraction Tissue
994 Decreased, Synthesis of molting fluid proteases Decreased, Synthesis of molting fluid proteases Tissue
995 Alterations, Food-web structures Alterations, Food-web structures Population
996 Decreased, Digestion of old cuticle Decreased, Digestion of old cuticle Organ
997 Decreased, Population size Decreased, Population size Population
998 Binding of antagonist, PPAR alpha Binding of antagonist, PPAR alpha Molecular
999 stabilization, co-repressor stabilization, co-repressor
1000 stabilization, PPAR alpha co-repressor stabilization, PPAR alpha co-repressor Molecular
1001 Increased, Developmental Defects Increased, Developmental Defects Molecular
1002 Inhibition, Deiodinase 2 Inhibition, Deiodinase 2 Molecular
1003 Decreased, Triiodothyronine (T3) in serum Decreased, Triiodothyronine (T3) in serum Cellular
1004 Reduced, Posterior swim bladder inflation Reduced, Posterior swim bladder inflation Organ
1005 Reduced, Swimming performance Reduced, Swimming performance Individual
1006 Reduced, Young of year survival Reduced, Young of year survival Individual
1007 Reduced, Anterior swim bladder inflation Reduced, Anterior swim bladder inflation Tissue
1008 Reduced, Hearing Reduced, Hearing Organ
1009 Inhibition, Deiodinase 1 Inhibition, Deiodinase 1 Molecular
1010 Activation, iGABAR chloride channel Activation, iGABAR chloride channel
1011 Increased, Chloride influx Increased, Chloride influx
1012 Increased, Inhibitory postsynaptic potential Increased, Inhibitory postsynaptic potential Cellular
1013 Inhibition, Motor neuron activity Inhibition, Motor neuron activity
1014 Induction, Somatic muscle paralysis Induction, Somatic muscle paralysis Tissue
1015 Increased, Neuronal synaptic inhibition Increased, Neuronal synaptic inhibition Cellular
1016 Inhibition, Feeding Inhibition, Feeding Individual
1017 Reduced, Feeding 2 Reduced, Feeding 2
1018 Activation, Glutamate-gated chloride channels Activation, Glutamate-gated chloride channels Molecular
1019 Induction, pharyngeal muscle paralysis Induction, pharyngeal muscle paralysis Tissue
1020 Increased, induction of UDPGT's in liver Increased, induction of UDPGT's in liver Cellular
1021 Increased, T4/T3 catabolism Increased, T4/T3 catabolism Cellular
1022 Decreased, serum T4/T3 Decreased, serum T4/T3 Tissue
1023 Increased, Thyroid-stimulating hormone (TSH) Increased, Thyroid-stimulating hormone (TSH) Tissue
1024 Increased, Hypertrophy and proliferation (follicular cell) Increased, Hypertrophy and proliferation (follicular cell) Cellular
1025 Increased, Hyperplasia (follicular cells) Increased, Hyperplasia (follicular cells) Tissue
1026 Increased Apoptosis, Adenomas/carcinomas (follicular cell) Increased Apoptosis, Adenomas/carcinomas (follicular cell) Tissue
1027 , Learning and memory, impairment , Learning and memory, impairment
1028 Activation of specific nuclear receptors, PPAR-gamma activation Activation of specific nuclear receptors, PPAR-gamma activation Molecular
1029 Increased, adipogenesis Increased, adipogenesis Cellular
1030 Increased, Increased,
1031 Increased, release of growth factors Increased, release of growth factors
1032 Increased, secretion of local growth factors Increased, secretion of local growth factors Cellular
1033 Increased, proliferation of mesenchymal cells Increased, proliferation of mesenchymal cells Cellular
1034 Increased, IGF-1 (mouse) Increased, IGF-1 (mouse) Cellular
1035 Increased, Firbrosarcoma Increased, Firbrosarcoma Tissue
1036 Increased, liposarcoma Increased, liposarcoma Tissue
1037 Increased, hemagiosarcoma Increased, hemagiosarcoma Tissue
1038 Activation, beta-2 adrenergic receptor Activation, beta-2 adrenergic receptor Molecular
1039 Increased activity, beta-2 adrenergic receptor Increased activity, beta-2 adrenergic receptor Molecular
1040 relaxation, smooth muscle relaxation, smooth muscle Tissue
1041 Proliferation, smooth muscle Proliferation, smooth muscle
1042 Proliferation/Clonal Expansion, smooth muscle Proliferation/Clonal Expansion, smooth muscle Cellular
1043 Hypertrophy/hyperplasia, smooth muscle Hypertrophy/hyperplasia, smooth muscle Cellular
1044 Promotion, mesovarian leiomyomas Promotion, mesovarian leiomyomas Tissue
1045 Decreased, Ovarian E2 Decreased, Ovarian E2 Tissue
1046 Suppression, Estrogen receptor (ER) activity Suppression, Estrogen receptor (ER) activity Molecular
1047 Increased, secretion of GnRH from hypothalamus Increased, secretion of GnRH from hypothalamus Cellular
1048 Increased, secretion of leutenizing hormone Increased, secretion of leutenizing hormone
1049 Increased, secrection of FSH from anterior pituitary Increased, secrection of FSH from anterior pituitary Cellular
1050 Increased, secretion of LH from anterior pituitary Increased, secretion of LH from anterior pituitary Cellular
1051 Hyperplasia, ovarian stromal cells Hyperplasia, ovarian stromal cells Cellular
1052 Hyperplasia, ovarian epithelium Hyperplasia, ovarian epithelium Tissue
1053 Promotion, ovarian adenomas Promotion, ovarian adenomas Tissue
1054 Promotion, ovarian granular cell tumors Promotion, ovarian granular cell tumors Cellular
1055 Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamu
1056 Decrease, E2 blood concentrations at hypothalamus Decrease, E2 blood concentrations at hypothalamus Tissue
1057 Increased, PPAR-alpha activation Increased, PPAR-alpha activation Molecular
1058 Decreased, bile flow Decreased, bile flow Organ
1059 Increased, cholestasis Increased, cholestasis Organ
1060 Alteration, lipid metabolism Alteration, lipid metabolism Cellular
1061 prolonged, elevation of serun CCK prolonged, elevation of serun CCK Tissue
1062 Increased, Cellular proliferation / hyperplasia of acinar cells Increased, Cellular proliferation / hyperplasia of acinar cells Cellular
1063 Increased, Pancreatic acinar tumors Increased, Pancreatic acinar tumors Organ
1064 prepubertal increase, Estrogen receptor (ER) activity prepubertal increase, Estrogen receptor (ER) activity Molecular
1065 Activation, estrogen receptor alpha Activation, estrogen receptor alpha Molecular
1066 Promotion, SIX-1 postive basal-type progenitor cells Promotion, SIX-1 postive basal-type progenitor cells Cellular
1067 Proliferation/Clonal Expansion, aberrant basal cells Proliferation/Clonal Expansion, aberrant basal cells Cellular
1068 squamous metaplasia, aberrant basal cells squamous metaplasia, aberrant basal cells Tissue
1069 Increased, Hyperplasia (glandular epithelial cells of endometrium) Increased, Hyperplasia (glandular epithelial cells of endometrium) Cellular
1070 Increased, adenosquamous carcinomas of endometrium Increased, adenosquamous carcinomas of endometrium Tissue
1071 Decreased, GnRH pulsatility/release in hypothalamus Decreased, GnRH pulsatility/release in hypothalamus Cellular
1072 Decreased, LH Surge from anterior pituitary Decreased, LH Surge from anterior pituitary Cellular
1073 anovulation, anovulation,
1074 interruption, Ovulation interruption, Ovulation Individual
1075 prolonged, estrus prolonged, estrus Individual
1076 Increased, circulating estrogen levels Increased, circulating estrogen levels Organ
1077 Increased, prolactin exposure Increased, prolactin exposure Tissue
1078 Hyperplasia, Mammary gland Hyperplasia, Mammary gland Tissue
1079 Increased, Adenomas/carcinomas (mammary) Increased, Adenomas/carcinomas (mammary) Tissue
1080 Increased, latency period Increased, latency period Individual
1081 Increased, lactotroph hyperplasia and hypertrophy Increased, lactotroph hyperplasia and hypertrophy Cellular
1082 Increased, adenomas (pituitary) Increased, adenomas (pituitary) Tissue
1083 Decreased, Dopaminergic activity Decreased, Dopaminergic activity Cellular
1084 Increased, prolactin secretion Increased, prolactin secretion Tissue
1085 Increased, hyperplasia (mammary gland) Increased, hyperplasia (mammary gland) Tissue
1086 persistent, cytotoxicity (pleura or peritoneum) persistent, cytotoxicity (pleura or peritoneum) Cellular
1087 Increased, inflammation Increased, inflammation Cellular
1088 Increased, Oxidative Stress Increased, Oxidative Stress Cellular
1089 Increased, Cell Proliferation (mesothelium) Increased, Cell Proliferation (mesothelium) Cellular
1090 Increased, mesotheliomas Increased, mesotheliomas Tissue
1091 Physical and/or chemical interaction with cellular components, Physical and/or chemical interaction with cellular components,
1092 Pulmonary Fibrosis, Pulmonary Fibrosis,
1093 Decreased, Thyroxine (T4) in tissues Decreased, Thyroxine (T4) in tissues Tissue
1094 , hyperuricemia , hyperuricemia
1095 hyperuricemia, hyperuricemia,
1096 Increased, blood uric acid concentration Increased, blood uric acid concentration Tissue
1097 Occurrence, renal proximal tubular necrosis Occurrence, renal proximal tubular necrosis Tissue
1098 Increased, blood potassium concentration Increased, blood potassium concentration Tissue
1099 Increased, mortality 2 Increased, mortality 2
1100 Occurrence, cardiac arrthymia Occurrence, cardiac arrthymia
1101 Altered, Amphibian metamorphosis Altered, Amphibian metamorphosis Organ
1102 Occurrence, tophi (urate) deposition Occurrence, tophi (urate) deposition Tissue
1103 Inhibition, Cyclooxygenase 1 activity Inhibition, Cyclooxygenase 1 activity Molecular
1104 Decreased, Prostaglandin F2alpha concentration, plasma Decreased, Prostaglandin F2alpha concentration, plasma Tissue
1105 Occurrence, renal ischemia Occurrence, renal ischemia Tissue
1106 Occurrence, cardiac arrhythmia Occurrence, cardiac arrhythmia Organ
1107 Weakened, Colony Weakened, Colony Population
1108 Abnormal, Role change within caste Abnormal, Role change within caste Population
1109 Increased, Deformed Wing Virus levels Increased, Deformed Wing Virus levels Individual
1110 Increased, Energetic demands and therefore metabolic stress Increased, Energetic demands and therefore metabolic stress Individual
1111 weaj, weaj,
1112 Occurrence, Oxidative Stress Occurrence, Oxidative Stress
1113 Unknown, Unknown,
1114 Unknown, MIE Unknown, MIE Molecular
1115 Increased, Reactive oxygen species Increased, Reactive oxygen species Cellular
1116 Decreased, Triiodothyronine (T3) in tissues Decreased, Triiodothyronine (T3) in tissues Tissue
1117 Irreversible inhibition of VKOR by binding at tyrosine 139, Irreversible inhibition of VKOR by binding at tyrosine 139,
1118 Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin
1119 Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII,
1120 Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form clot Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form cl
1121 Hemorrhage , organ dysfunction, hypovolemic shock Hemorrhage , organ dysfunction, hypovolemic shock
1122 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur Tissue
1123 Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue
1124 Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon diox
1125 Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and other waste products, Hemorrhage, organ dysfunction and hypovolemic shock Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and oth
1126 Unresolved blood loss, Failure in vascular repair mechanisms Unresolved blood loss, Failure in vascular repair mechanisms
1127 Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste
1128 Unresolved hemorrhage, Failure in vascular repair mechanisms Unresolved hemorrhage, Failure in vascular repair mechanisms
1129 Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms
1130 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Organ
1131 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo Molecular
1132 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis Cellular
1133 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Tissue
1134 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle Molecular
1135 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Tissue
1136 Impaired recruitment , Population trajectory Impaired recruitment , Population trajectory Population
1137 Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form
1138 Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Molecular
1139 Increased, water retention in foot Increased, water retention in foot Organ
1140 Delayed, Sexual maturity Delayed, Sexual maturity Individual
1141 Decreased, Reproductive Success Decreased, Reproductive Success Individual
1142 Increased, valve movement Increased, valve movement Tissue
1143 Depletion, energy reserves Depletion, energy reserves Individual
1144 premature, spawning 1 1 premature, spawning 1
1145 Decreased, gametogenesis Decreased, gametogenesis
1146 premature, Spawning premature, Spawning Individual
1147 increased or inappropriate, mantel display increased or inappropriate, mantel display Individual
1148 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of protein synthesis in bone Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p
1149 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone proteins (periostin, MGP and periostin like factor) not formed Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1150 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Impaired function of osteocalcin and MGP Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1151 Osteoporosis and vascular calcification, Bone deterioration Osteoporosis and vascular calcification, Bone deterioration Individual
1152 Inhibition, Iodotyrosine deiodinase (IYD) Inhibition, Iodotyrosine deiodinase (IYD) Molecular
1153 Inhibition, Deiodinase 3 Inhibition, Deiodinase 3 Molecular
1154 Increased, Triiodothyronine (T3) in tissues Increased, Triiodothyronine (T3) in tissues Tissue
1155 Inhibition, Pendrin Inhibition, Pendrin Molecular
1156 Inhibition, Dual oxidase Inhibition, Dual oxidase Molecular
1157 Activation, Hepatic nuclear receptor(s) Activation, Hepatic nuclear receptor(s) Molecular
1158 Increased, Hepatic thyroid hormone uptake/transport Increased, Hepatic thyroid hormone uptake/transport Tissue
1159 Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin transporter Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin tr
1160 Increased, mantel display Increased, mantel display Individual
1161 Increased, oocyte maturation Increased, oocyte maturation Organ
1162 Increased, cilia movement Increased, cilia movement Cellular
1163 Increased, Reproductive Success Increased, Reproductive Success Individual
1164 Increased, Population Increased, Population Population
1165 Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone proteins e.g., periostin Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone prot
1166 Increased, water pumping Increased, water pumping Tissue
1167 induced, parturition induced, parturition Individual
1168 Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interaction, bone resorption) and glucose and lipid hoemostasis Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interacti
1169 Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment Molecular
1170 modulation, Genes/proteins that regulate hepatocyte fate modulation, Genes/proteins that regulate hepatocyte fate Cellular
1171 Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Cellular
1172 Increase activation, Nuclear factor kappa B (NF-kB) Increase activation, Nuclear factor kappa B (NF-kB) Molecular
1173 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
1174 Activation, NADPH Oxidase Activation, NADPH Oxidase Molecular
1175 Increase, Genes involved in fatty acid oxidation Increase, Genes involved in fatty acid oxidation Cellular
1176 Decreased, sodium conductance 2 Decreased, sodium conductance 2 Cellular
1177 Decreased, Ionotropic GABA receptor chloride channel conductance Decreased, Ionotropic GABA receptor chloride channel conductance Cellular
1178 Decreased, Chloride conductance Decreased, Chloride conductance
1179 Decreased, GABA release Decreased, GABA release Cellular
1180 Estrogen receptor activation, Estrogen receptor activation,
1181 Activation, Estrogen receptor Activation, Estrogen receptor Molecular
1182 Increase, Cell Proliferation (Epithelial Cells) Increase, Cell Proliferation (Epithelial Cells) Cellular
1183 Decreased, Apoptosis (Epithelial Cells) Decreased, Apoptosis (Epithelial Cells) Cellular
1184 Dysfunction, Mitochondrial Dynamics Dysfunction, Mitochondrial Dynamics
1185 Mitochondrial Dysfunction, N/A Mitochondrial Dysfunction, N/A
1186 N/A, Mitochondrial Dysfunction 2 N/A, Mitochondrial Dysfunction 2
1187 Increased, ER binding to DNA (classical pathway) Increased, ER binding to DNA (classical pathway) Molecular
1188 Increased, ER binding to T.F. to DNA (non-classical pathway) Increased, ER binding to T.F. to DNA (non-classical pathway) Molecular
1189 Increased, Proliferation (Endothelial cells) Increased, Proliferation (Endothelial cells) Cellular
1190 Increased, Migration (Endothelial Cells) Increased, Migration (Endothelial Cells) Cellular
1191 Increased, Non-genomic signaling Increased, Non-genomic signaling Cellular
1192 Increased, Ductal Hyperplasia Increased, Ductal Hyperplasia Tissue
1193 N/A, Breast Cancer N/A, Breast Cancer Individual
1194 Increased, DNA Damage Increased, DNA Damage Molecular
1195 modulation, Extracellular Matrix Composition modulation, Extracellular Matrix Composition Cellular
1196 Increased, Invasion Increased, Invasion Cellular
1197 Activation, Fibroblasts Activation, Fibroblasts Cellular
1198 Activation, Macrophages Activation, Macrophages Cellular
1199 Binding of FK506 to FKBP12, Binding of FK506 to FKBP12,
1200 Binding of FK506 to FKBP12, Formation Binding of FK506 to FKBP12, Formation
1201 Binding, Immunophilins Binding, Immunophilins Molecular
1202 Suppression, IL-2 and IL-4 production Suppression, IL-2 and IL-4 production Cellular
1203 Suppression, Suppression of production of cytotoxic T-cells Suppression, Suppression of production of cytotoxic T-cells Tissue
1204 Suppression, Suppression of T-cell dependent antibody production Suppression, Suppression of T-cell dependent antibody production Cellular
1205 Activation, Juvenile hormone receptor Activation, Juvenile hormone receptor Molecular
1206 Induction, Doublesex1 gene Induction, Doublesex1 gene Molecular
1207 Induction, Male traits formation in embryos Induction, Male traits formation in embryos
1208 Increased, Male offspring Increased, Male offspring Population
1209 Induction, Male reproductive tract Induction, Male reproductive tract Organ
1210 Alteration, Food-web structures Alteration, Food-web structures Population
1211 Altered, food-web structures Altered, food-web structures Population
1212 Reduced, Neuronal synaptic inhibition Reduced, Neuronal synaptic inhibition Cellular
1213 Increased, Angiogenesis Increased, Angiogenesis Cellular
1214 Altered gene expression specific to CAR activation, Hepatocytes Altered gene expression specific to CAR activation, Hepatocytes Cellular
1215 TRPA1 activation, TRPA1 Receptor TRPA1 activation, TRPA1 Receptor Molecular
1216 Influx of Ca2+, Excitation of trigeminal nerves Influx of Ca2+, Excitation of trigeminal nerves
1217 Sensory airway irritation, Excitation of trigeminal nerves Sensory airway irritation, Excitation of trigeminal nerves
1218 Opening of calcium channel, Calcium influx Opening of calcium channel, Calcium influx Cellular
1219 Release of Substance P (SP), Substance P increase in circulation Release of Substance P (SP), Substance P increase in circulation
1220 Excitation, Neuron nerve ending excitation Excitation, Neuron nerve ending excitation Cellular
1221 Cough, Dyspnea, Sneezing, Acute respiratory effect Cough, Dyspnea, Sneezing, Acute respiratory effect
1222 SP (Substance P) release, Local increase of SP SP (Substance P) release, Local increase of SP Cellular
1223 Airway Hyper-responsiveness,Cough, Dyspnea, Trigeminal and/or vagal nerve excitation Airway Hyper-responsiveness,Cough, Dyspnea, Trigeminal and/or vagal nerve excitation Tissue
1224 Non-neuronal production of TNF, Epithelial irritation Non-neuronal production of TNF, Epithelial irritation Individual
1225 Immune system inflammation Leukocyte infiltration Tissue
1226 Chronic Cough, Respiratory irritability Chronic Cough, Respiratory irritability Individual
1227 TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NEK293 fibroblast cells TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NE
1228 TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary), noncovalently linkked) TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary),
1229 TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ HEK293 fibroblast cells TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ H
1230 TRPV1 activation, TRPV1 TRPV1 activation, TRPV1 Molecular
1231 Oxidization of biomolecules, Lipid bilayer and cellular proteins Oxidization of biomolecules, Lipid bilayer and cellular proteins
1232 Production of nerve growth factor , Production of nerve growth factor ,
1233 Production, Nerve growth factor Production, Nerve growth factor
1234 Production of nerve growth factor , Epithelial irritation Production of nerve growth factor , Epithelial irritation Tissue
1235 Non-neuronal production of IL-8/CXCL1, Epithelial irritation Non-neuronal production of IL-8/CXCL1, Epithelial irritation Tissue
1236 Generation of novel epitopes , Antigen presentation Generation of novel epitopes , Antigen presentation Cellular
1237 Sensitization, Immune system Sensitization, Immune system Individual
1238 Activation of oxidative stress pathway Oxidation Molecular
1239 Altered, Gene Expression Altered, Gene Expression Molecular
1240 Altered, Protein Production Altered, Protein Production Cellular
1241 Increased, Motility Increased, Motility Cellular
1242 Increased, Second Messenger Production Increased, Second Messenger Production Cellular
1243 Altered, Ca2+-calmodulin activated signal transduction Altered, Ca2+-calmodulin activated signal transduction Cellular
1244 Mucus hypersecretion, Mucus hypersecretion,
1245 Mucus , Hypersecretion Mucus , Hypersecretion
1246 Lung function, Decrease Lung function, Decrease
1247 EGFR , PPAR-alpha activation EGFR , PPAR-alpha activation
1248 EGFR , Activation EGFR , Activation
1249 Oxidative Stress, Oxidative Stress,
1250 Decrease, Lung function Decrease, Lung function Individual
1251 Chronic, Mucus hypersecretion Chronic, Mucus hypersecretion Tissue
1252 In-utero DNA topoisomerase II “poisons- DNA topoisomerase II “poisons” Molecular
1253 In utero MLL chromosomal translocation MLL translocation Cellular
1254 Infant leukaemia IFL Individual
1255 induced spawning induced spawning Individual
1256 increased mantel display increased mantel display Organ
1257 Induced parturition Induced parturition Individual
1258 Decompartmentalization Decompartmentalization Cellular
1259 narcosis narcosis Cellular
1260 Direct mitochondrial inhibition Direct mitochondrial inhibition Molecular
1261 Mitochondrial impairment Mitochondrial impairment Molecular
1262 Apoptosis Apoptosis Tissue
1263 Necrosis Necrosis Tissue
1264 Induction, Nuclear receptor E75b gene Induction, E75b gene Molecular
1265 Suppression, Fushi tarazu factor-1 gene Suppression, Ftz-f1 gene Molecular
1266 Reduction, Release of circulating crustacean cardioactive peptide Reduction, Release of circulating CCAP Tissue
1267 Reduction, Ecdysis motoneuron bursts Reduction, Ecdysis motoneuron bursts Tissue
1268 Reduction, Excitatory postsynaptic potential Reduction, Excitatory postsynaptic potential Tissue
1269 Increase, COX-2 expression Increase, COX-2 expression Molecular
1270 Inactivation of PPARγ Inactivation of PPARγ Molecular
1271 Activation of TGF-β signaling Activation of TGF-β signaling Cellular
1272 Differentiation of Myofibroblast Differentiation of Myofibroblast Cellular
1273 Expression of Collagen Expression of Collagen Cellular
1274 Production of α-smooth muscle actin Production of α-smooth muscle actin Cellular
1275 Collagen Deposition Collagen Deposition Tissue
1276 Lung fibrosis Lung fibrosis Organ
1277 Reproductive failure Reproductive failure Individual
1278 ROS formation ROS formation Molecular
1279 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Cellular
1280 Activation, HIF-1 Activation, HIF-1 Cellular
1281 Increased, DNA Damage-Repair Increased, DNA Damage-Repair Cellular
1282 Activation, JAK/STAT pathway Activation, JAK/STAT pathway Cellular
1283 Activation, TGF-beta pathway Activation, TGF-beta pathway Cellular
1284 Up Regulation, SREBF2 Up Regulation, SREBF2 Cellular
1285 Up Regulation, Unsaturated fatty acid Up Regulation, Unsaturated fatty acid Cellular
1286 Down Regulation, GSS and GSTs gene Down Regulation, GSS and GSTs gene Cellular
1287 Glutathione synthesis Glutathione synthesis Cellular
1288 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Cellular
1289 Perturbation of cholesterol Perturbation of cholesterol Cellular
1290 Glutathione homeostasis Glutathione homeostasis Cellular
1291 Hepatotoxicity Hepatotoxicity Cellular
1292 Activation, JNK Activation, JNK Cellular
1293 Activation, FOXO Activation, FOXO Cellular
1294 Inhibition, Wnt pathway Inhibition, Wnt pathway Cellular
1295 Defect of Embryogenesis Defect of Embryogenesis Tissue
1296 Increase, insulin Increase, insulin Molecular
1297 Activation, insulin receptor Activation, insulin receptor Molecular
1298 Activation, mTORC2 Activation, mTORC2 Molecular
1299 Activation, AKT Activation, AKT Molecular
1300 Activation, mTORC1 Activation, mTORC1 Molecular
1301 Activation, SREBP-1 Activation, SREBP-1 Molecular
1302 Activation, L-FABP Activation, L-FABP Molecular
1303 Activation, HSD17B4 Activation, HSD17B4 Molecular
1304 Activation, FXR Activation, FXR Molecular
1305 Increase, cytosolic fatty acid Increase, cytosolic fatty acid Molecular
1306 Increased, lipogenesis Increased, lipogenesis Molecular
1307 Inhibition, LXR Inhibition, LXR Molecular
1308 Inhibition, LRH-1 Inhibition, LRH-1 Molecular
1309 Activation, aPKC Activation, aPKC Molecular
1310 Activation, PI3K Activation, PI3K Molecular
1311 Inhibition, Steatosis Inhibition, Steatosis Organ
1312 Induction, fatty acid beta-oxidation Induction, fatty acid beta-oxidation Molecular
1313 Decrease, cytosolic fatty acid Decrease, cytosolic fatty acid Molecular
1314 Activation, LRH-1 Activation, LRH-1 Molecular
1315 Increase, Selective Serotonin Reuptake Inhibitors (SSRIs) Increase, SSRIs Molecular
1316 Inhibit, serotonin transporter activity Inhibit, serotonin transporter activity Molecular
1317 Decreased, serotonin transporter activity Decreased, serotonin transporter activity Molecular
1318 Decreased, extracellular sodium (Na+) Decreased, extracellular Na+ Molecular
1319 Decreased, extracellular chloride (Cl-) Decreased, extracellular chloride (Cl-) Molecular
1320 Increased, extracellular serotonin Increased, extracellular serotonin Molecular
1321 Increased, intracellular sodium (Na+) Increased, intracellular sodium (Na+) Molecular
1322 Increased, intracellular chloride (Cl-) Increased, intracellular chloride (Cl-) Molecular
1323 Decreased, intracellular serotonin Decreased, intracellular serotonin Molecular
1324 Decreased, packaged serotonin Decreased, packaged serotonin Molecular
1325 Decreased, synaptic release Decreased, synaptic release Molecular
1326 Increased, 5-HT3 (5-hydroxytryptamine) Increased, 5-HT3 Molecular
1327 Decreased, seizure Decreased, seizure Individual
1328 Inactivated, 5-HTR (serotonin receptors) Inactivated, 5-HTR Molecular
1329 Reduce expression, BDNF (Brain-derived neurotrophic factor) Reduce expression, BDNF Molecular
1330 Decreased, neuroplasticity Decreased, neuroplasticity Molecular
1331 Inhibit, agitation Inhibit, agitation Individual
1332 Inhibit, depression Inhibit, depression Individual
1333 Increase, mental stress Increase, mental stress Individual
1334 Increase, cortisone Increase, cortisone Molecular
1335 Reduced, BDNF (Brain-derived neurotrophic factor) Reduced, BDNF Molecular
1336 Activation, 5-HT2A (Serotonin 2A) Activation, 5-HT2A Molecular
1337 Activate, PLC (Phospholipase C) Activate, PLC Molecular
1338 Increase, inositol triphosphate Increase, inositol triphosphate Molecular
1339 Increase, intracellular calcium Increase, intracellular calcium Cellular
1340 Activate, calmodulin Activate, calmodulin Molecular
1341 Increase, myosin light chain phosphorylation Increase, myosin light chain phosphorylation Molecular
1342 Increase, vascular smooth muscle contraction Increase, vascular smooth muscle contraction Molecular
1343 Increase, hypertension Increase, hypertension Individual
1344 Increased, seizure Increased, seizure Individual
1345 Increased, agitation Increased, agitation Molecular
1346 Increased, depression Increased, depression Individual
1347 Decreased, extracellular serotonin Decreased, extracellular serotonin Molecular
1348 Increase, seizure Increase, seizure Individual
1349 Activated, presynaptic neuron 1 Activated, presynaptic neuron 1 Molecular
1350 Increased, glutamate Increased, glutamate Molecular
1351 Activated, NMDA receptor Activated, NMDA receptor Molecular
1352 Activated, voltage-gated sodium channel Activated, voltage-gated sodium channel Molecular
1353 Inhibit, voltage-gated sodium channel Inhibit, voltage-gated sodium channel Molecular
1354 Treat, carbamazepine Treat, carbamazepine Molecular
1355 Activated, membrane depolarization Activated, membrane depolarization Cellular
1356 Inactive, membrane depolarization Inactive, membrane depolarization Molecular
1357 Increased, RDX dose Increased, RDX dose Molecular
1358 Repress, GABA-A receptor Repress, GABA-A receptor Molecular
1359 Activate, GABA-A receptor Activate, GABA-A receptor Molecular
1360 Activate, presynaptic neuron 2 Activate, presynaptic neuron 2 Molecular
1361 Increase, GABA Increase, GABA Molecular
1362 Increased, hippocampal hyperdepolarization Increased, hippocampal hyperdepolarization Molecular
1363 Increased, epilepsy Increased, epilepsy Individual
1364 Excessive reactive oxygen species formation Excessive ROS formation Molecular
1365 Increase, Apoptosis Increase, Apoptosis Cellular
1366 Decrease, Oogenesis Decrease, Oogenesis Cellular
1367 Inhibit, gastric ulcer formation Inhibit, gastric ulcer formation Organ
1368 Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Inhibition, PTGS-1 Molecular
1369 Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Activation, PTGS-1 Molecular
1370 Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Activation, PTGS-2 Molecular
1371 Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Molecular
1372 Increase, bicarbonate Increase, bicarbonate Molecular
1373 Increase, mucous Increase, mucous Molecular
1374 Increase, mucosal blood flow Increase, mucosal blood flow Tissue
1375 Increase, platelet aggregation Increase, platelet aggregation Tissue
1376 Increase, angiogenesis Increase, angiogenesis Tissue
1377 Decrease, leukocyte adherence Decrease, leukocyte adherence Tissue
1378 Increase, leukocyte adherence Increase, leukocyte adherence Tissue
1379 Activate, leukocyte Activate, leukocyte Cellular
1380 Activate, mucosal defense Activate, mucosal defense Tissue
1381 Increase, surfactant Increase, surfactant Molecular
1382 Decrease, surfactant Decrease, surfactant Molecular
1383 Activate, phospholipase Activate, phospholipase Molecular
1384 Increase, ammonium (NH4+) Increase, ammonium (NH4+) Molecular
1385 Activated, gastric ulcer formation Activated, gastric ulcer formation Organ
1386 CYP7B activity, inhibition CYP7B activity, inhibition Molecular
1387 7α-hydroxypregnenolone synthesis in the brain, decreased 7α-hydroxypregnenolone synthesis in the brain, decreased Cellular
1388 Dopamine release in the brain, decreased Dopamine release in the brain, decreased Tissue
1389 Locomotor activity, decreased Locomotor activity, decreased Individual
1390 Sexual behavior, decreased Sexual behavior, decreased Individual
1391 Activation of Cyp2E1 in the liver Activation of Cyp2E1 in the liver Molecular
1392 Oxidative Stress Oxidative Stress Molecular
1393 Hepatocytotoxicity Hepatocytotoxicity Cellular
1394 Hepatocellular Regenerative Proliferation Hepatocellular Regenerative Proliferation Cellular
1395 Liver Cancer Liver Cancer Organ
1396 Increased, glucocorticoid receptor activity Increased, glucocorticoid receptor activity Molecular
1397 Increased, serotonin transporter activity Increased, serotonin transporter activity Cellular
1398 Increased, intracellular serotonin Increased, intracellular serotonin Cellular
1399 Increased, packaged serotonin Increased, packaged serotonin Cellular
1400 Increased, synaptic release Increased, synaptic release Cellular
1401 Decreased, 5-HT3 Decreased, 5-HT3 Tissue
1402 Reduced, PTGS1 function Reduced, PTGS1 function Molecular
1403 Reduced, platelet aggregation Reduced, platelet aggregation Tissue
1404 Decreased, mucosal blood flow Decreased, mucosal blood flow Tissue
1405 Reduced, mucosal defense Reduced, mucosal defense Tissue
1406 Decreased, mucous Decreased, mucous Tissue
1407 Decreased, bicarbonate Decreased, bicarbonate Tissue
1408 Reduced, PTGS2 function Reduced, PTGS2 function Cellular
1409 Decreased, angiogenesis Decreased, angiogenesis Tissue
1410 Increased, leukocyte adherence Increased, leukocyte adherence Tissue
1411 Increased, leukocyte activation Increased, leukocyte activation Tissue
1412 Helicobacter pylori infection Helicobacter pylori infection Tissue
1413 Reduced, presynaptic neuron 2 activity Reduced, presynaptic neuron 2 activity Cellular
1414 Decreased, GABA Decreased, GABA Cellular
1415 Reduced, GABA-A receptor activation Reduced, GABA-A receptor activation Molecular
1416 Decreased, intracellular chloride Decreased, intracellular chloride Cellular
1417 NFE2/Nrf2 repression NFE2/Nrf2 repression Molecular
1418 Increased, steatosis Increased, steatosis Organ
1419 Reduced, FXR activity Reduced, FXR activity Molecular
1420 Reduced, SHP activity Reduced, SHP activity Molecular
1421 Activated, LXR Activated, LXR Molecular
1422 Reduced, PPARalpha Reduced, PPARalpha Molecular
1423 Reduced, HSD17B4 activity Reduced, HSD17B4 activity Molecular
1424 Reduced, fatty acid beta oxidation Reduced, fatty acid beta oxidation Molecular
1425 Mu Opioid Receptor Agonism Mu Opioid Receptor Agonism Molecular
1426 Release of G Proteins Release of G Proteins Cellular
1427 Opening of G protein gated inward rectifying K channels Opening of GIRK channels Cellular
1428 Analgesia Analgesia Individual
1429 Inhibition of N-type Ca ion channels Inhibition of Ca Channels Cellular
1430 Inhibition of neurotransmitter vesicle release Inhibition of neurotransmitter release Cellular
1431 Serotonin 1A Receptor Agonism Serotonin 1A Receptor Agonism Molecular
1432 Anti-depressant Activity Anti-depressant Activity Individual
1433 Increased CGRP, neuronal release of CGRP Increased CGRP Cellular
1434 Irritation of nasal mucosa inducing sneeze reflex Irritation induced sneezing Tissue
1435 Increased neurokinin A (NKA) by neuronal cells Increased NKA Cellular